Neurocrine Biosciences (NBIX): A Top Biotech With 15%+ Growth Potential?
Автор: The Motley Fool
Загружено: 2025-03-26
Просмотров: 1066
On this episode of Scoreboard, Motley Fool analysts Keith Speights and Karl Thiel analyze Neurocrine Biosciences [NBIX], a brain-focused biotech with promising products and a solid balance sheet. With growing sales of Ingrezza, a new rare disease launch, and potential pipeline breakthroughs, could NBIX be a 15%+ gainer over the next five years?
------------------------------------------------------------------------
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 803% as of 3/14/2025 and measured against the S&P 500 returns of 160% as of 3/14/2025. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
